Edwards to roll out Physio II
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences will launch its Carpetier-Edwards Phyiso II mitral valve annuloplasty repair ring in the U.S. and Europe in the first quarter of 2009, and expects it to help drive a 15% revenue boost in its heart valve therapy division to nearly $670 million in 2009, the company announces during its Feb. 3 fourth-quarter earnings call. FDA recently cleared Physio II via 510(k) and the device also has CE mark approval. Physio II is the only annuloplasty ring to offer "shape optimization" that matches the shape of the ring to the shape of the patient's diseased valve, according to Edwards. It also features a unique sewing cuff, making it easier for surgeons to implant, according to the company
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.